Background:
In the modern era of effective antiretroviral therapy (ART), people living with HIV (PLWH) have near-normal life-expectancies, but two times higher occurrence of cardiovascular disease (CVD) that is associated with some antiretrovirals. We have previously reported that certain nucleotide reverse transcriptase inhibitors (NRTIs) enhance platelet and endothelial activation promoting a pro-thrombotic phenotype. Little is known, however, about the off-target cellular effects of integrase inhibitors (INSTIs). Here, we aimed to compare the effects of two commonly prescribed INSTIs, bictegravir (BIC) and dolutegravir (DTG) on platelet activation to better understand their comparative off-target effects on CVD risk.
Methods:
Platelets were isolated from whole blood obtained by informed consent from HIV-negative donors (60% male, aged 25 ±3 yrs). Platelets were exposed in vitro to clinical plasma Cmax concentrations of BIC, DTG or vehicle (Veh) control for 30min. Platelet activation was assessed in response to collagen [1-30μg/ml], ADP or thrombin receptor activator peptide (TRAP)-6 [1-30μM] by light transmission aggregometry and flow cytometry. Results were statistically analysed using a 2-way ANOVA with a Tukey’s multiple comparison test.
Results:
DTG treatment induced a significantly higher degree of ADP-evoked platelet aggregation compared to BIC (+1.79-fold, p=0.0271) and Veh (+1.82-fold, p=0.0040) at low ADP concentrations [3μΜ]. Similar effects were observed with TRAP-6 [10μΜ], with DTG-treated platelets showing higher aggregation compared to BIC (+1.45-fold, p=0.0110) and Veh (+1.88-fold, p=0.0131) treatment. Collagen-activated platelets [3μg/ml] exposed to DTG had +1.94-fold higher percentage aggregation compared to Veh group (p=0.0188). No significant changes in platelet degranulation were observed between the different groups.
Conclusions:
Our results suggest that DTG may make platelets more sensitive to low level ADP and collagen stimulation, through an as yet undiscovered activation mechanism. This may suggest that DTG, but not BIC, has the potential to increase CVD risk. Further evaluation of platelet activation in vivo and in clinical settings is required to determine the contrasting off-target effects of DTG and BIC in patients. Ultimately, this work may lead to the identification of treatment regimens with a lower CVD risk, providing a safer option when treating PLWH.